Adial Pharmaceuticals, Inc. ADIL
5.05 USD +1.34 (+36.12%)
At closeOct 28, 2026, 4:00 PM EDT
4.86 -0.19 -3.76%
After hours · Oct 28, 4:00 PM ET
3.82 Day range 5.15
3.81 52-week range 5.05
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 13.26M
- EPS (ttm)
- -20.65
- Shares out
- 6.41M
- Forward P/E
- -0.79
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 83.08K
- Avg volume
- 58.15K
- Open
- 3.83
- Previous close
- 3.71
- Day's range
- 3.82 – 5.15
- 52-week range
- 3.81 – 5.05
- Beta
- 1.30
- Price target
- 7.50 (+48.5%)
- Earnings date
- Aug 13, 2024
YTD -0.96 (-19.01%)
Key statistics
- Enterprise value
- 4.01M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -2.99M
- Total cash
- 3.29M
- Total debt
- 0
- Return on equity
- -320.96%
- Short % of float
- 1.25%
- 50-day average
- 1.06
- 200-day average
- 1.23
Analyst view
Price target (mean) 7.50 +48.5% upside
Now 5.05
- Target (low)
- 7.00
- Target (mean)
- 7.50
- Target (high)
- 8.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.33.
Financials — quick view
ADIL Revenue — quarterly 0
ADIL Net income — quarterly -51.99M
ADIL EPS — quarterly -11.25
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.50 | -0.38 | +0.12 | +24.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.39 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.39 | -0.59 | -0.20 | -51.28% |
| May 14, 2024 | Mar 1, 2024 | -0.51 | -0.68 | -0.17 | -33.33% |
| May 14, 2024 | Mar 1, 2024 | -0.51 | — | — | — |
| Apr 4, 2024 | Dec 1, 2023 | -0.89 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | init | — | Buy |
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- adialpharma.com
News
Adial Pharmaceuticals Plans To Change Corporate Name To Azora Therapeutics, Nasdaq Ticker to AZR, Effective Oct. 29 
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis 
Adial Pharmaceuticals Expects To Appoint Celia Economides As CFO At Its Annual Meeting, Succeeding Vinay Shah 
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer 
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis 
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) 
12 Health Care Stocks Moving In Friday's Intraday Session 
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on ADIL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLAIBORNE CARY J | Chief Executive Officer | Stock Award(Grant) | May 22, 2023 | 1,520,000 |
| SCHUYLER KEVIN | Director | Purchase | Sep 28, 2023 | 6,589 |
| STILLEY WILLIAM B. III | Director | Stock Award(Grant) | May 22, 2023 | 1,261,780 |
| TRULUCK JOSEPH | Chief Financial Officer | Stock Award(Grant) | May 22, 2023 | 265,139 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Manchester Capital Management, LLC | 0.75% | 48,097 | 50.50K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.71% | 45,466 | 47.74K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.52% | 33,270 | 34.93K | Sep 29, 2024 |
| Blackrock Inc. | 0.43% | 27,770 | 29.16K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.42% | 27,115 | 28.47K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 4,404 | 4.62K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.55% | 35,139 | 36.90K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.15% | 9,359 | 9.83K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 9,158 | 9.62K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 7,754 | 8.14K | Oct 30, 2024 |